Blueprint Bio, Inc., a company dedicated to identifying, validating, protecting, publishing and licensing new biological discoveries in the healthcare industry, has announced that Edward Jensen will be joining the executive team, effective immediately. He will assume the position of Chief Operating Officer and will be responsible for all strategic operations and execution.
Edward has over 30 years’ successful leadership and managerial experience – driving innovation, development, and commercialization in diverse global, multi-national business environments and has a demonstrable track record of consistently delivering on strategic business objectives. His substantial in-depth, broad-based, hands-on experience in most aspects of pharmaceutical drug development and commercialization with previous assignments in early research, manufacturing, clinical development & regulatory submissions through to product launch make him the ideal person to assume the role of COO for the company. Prior to joining Blueprint, Edward held a number of senior leadership positions at major pharmaceutical companies including Johnson & Johnson, Biogen, AstraZeneca and the TransCelerate industry collaboration.
“This is, arguably, the most ground-breaking start-up opportunity in the healthcare industry at this moment,” said Edward Jensen. “I am extremely honored, excited and energized to be part of this unique venture.”
“Edward’s intimate knowledge of the challenges experienced in drug development and his background in process optimization, time and project management, budgeting and resource allocation will be critical as the company moves to commercialize the assets we have developed,” stated Matthew Nunez, CEO of Blueprint. “With our pipeline, intellectual property and plans to develop multiple highly predictive diagnostics, I am convinced that we have found the ideal person to accelerate our progress.”